- Kraig Biocraft Laboratories (OTCQB: KBLB) successfully launches a next-generation gene-splicing platform.
- New transgenic silkworm created, now under evaluation for commercial applications.
- Platform to enhance R&D speed, DNA manipulation precision, and production efficiency.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), a leader in spider silk technology, announced the successful rollout of a next-generation molecular biology and gene-splicing platform. This advancement represents a significant enhancement in the company's genetic engineering abilities, particularly for spider silk production.
Using cutting-edge advancements in gene editing, Kraig Labs has created a new transgenic silkworm. This innovation is now undergoing evaluation testing and commercial application assessment, marking a critical step forward in its technology validation process.
By adopting this platform, Kraig Labs aims to achieve more precise, efficient, and versatile DNA manipulation, which is expected to accelerate the research and development pipeline for advanced materials. The company is currently experimenting with two such gene-editing platforms and plans to choose one for all ongoing and future commercial silkworm development programs.
This strategic shift is anticipated to drive increased efficiency, consistency, and performance in spider silk production, aligning with the company's mission to commercialize high-performance spider silk materials for diverse markets, including technical textiles, defense, performance apparel, and medical textiles.
For more information and updates on Kraig Labs' pioneering technologies, visit their official website at www.kraiglabs.com.
